Waldencast Full Year 2023 Earnings: EPS Misses Expectations
Telsey Advisory Group Maintains Outperform on Waldencast, Lowers Price Target to $8
Telsey Advisory Group analyst Dana Telsey maintains Waldencast with a Outperform and lowers the price target from $10 to $8.
Understanding the Risks: Potential Share Dilution and Market Challenges Facing Waldencast Acquisition Corp.
Waldencast 2023 Rev $218.1M >WALD
Waldencast 2023 Rev $218.1M >WALD
Press Release: Waldencast Reports Fiscal Year 2023 Financial Results
Waldencast Reports Fiscal Year 2023 Financial Results 2023 Net Revenue of $218.1 million Group Combined Comparable Revenue of $212.5 million, a 15.3% increase vs 2022 Group Combined Adjusted EBITDA
Waldencast Plc's (NASDAQ:WALD) Stock Price Dropped 8.3% Last Week; Private Companies Would Not Be Happy
Key Insights Significant control over Waldencast by private companies implies that the general public has more power to influence management and governance-related decisions 54% of the business is h
Waldencast Regains Nasdaq Compliance With Requirements
Waldencast Back in Line With Nasdaq Rules
Waldencast Receives Formal Notice Confirming That It Has Regained Compliance With Nasdaq Filing Requirements
Waldencast Receives Formal Notice Confirming That It Has Regained Compliance With Nasdaq Filing Requirements
Waldencast Acquisition (WALD) Receives a Buy From Telsey Advisory
Waldencast Is Maintained at Outperform by Telsey Advisory Group
Waldencast Is Maintained at Outperform by Telsey Advisory Group
Telsey Advisory Group Maintains Outperform on Waldencast, Lowers Price Target to $10
Telsey Advisory Group analyst Dana Telsey maintains Waldencast with a Outperform and lowers the price target from $12 to $10.
Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected
US stocks look set to open higher in Thursday's trading session as investors parse jobless and manufacturing data released earlier this morning and look ahead to home sales data set for release later
Waldencast Posts Strong H1 2023 Financials
Obagi Cosmeceuticals Announces the Launch of Daily Hydro-Drops Rejuvenating Eye Gel Cream
LONG BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Obagi Cosmeceuticals LLC ("Obagi"), a leader in skincare innovation and the originator of medical-grade skincare and a subsidiary of Waldencast plc, (NASDAQ:WALD)
Waldencast Retains Nasdaq Listing With Conditions
Waldencast Plc (WALD, WALDW) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)--$WALD #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Waldencast plc ("Waldencast" or "t
Waldencast Announces New "Creative Council" of Industry Pioneers and Disruptors
NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast" or "the Company"), a global multi-brand beauty and wellness platform, today announced the formation of a new Creative Council. The
Press Release: Dr. Suzan Obagi Appointed as Chief Medical Director at Obagi Cosmeceuticals, a Subsidiary of Waldencast Plc.
Dr. Suzan Obagi Appointed as Chief Medical Director at Obagi Cosmeceuticals, a Subsidiary of Waldencast plc. LONG BEACH, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Obagi Cosmeceuticals LLC ("Obagi"),
Waldencast and Calavo Growers Under Legal Scrutiny for Potential Violations
No Data